DERMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Derma Sciences, Inc. (DSCI) Over the Proposed Sale of the Company to Integra LifeSciences Holdings Corporation

NEW YORK, Jan. 13, 2017

The Company's stockholders will only receive $7.00 in cash for each share of Company common stock they own. However, this consideration is below at least one analyst's price target of $8.50 per share.

Click here for more information: www.faruqilaw.com/DSCI.  There is no cost or obligation to you.

The investigation focuses on whether Derma's Board of Directors breached their fiduciary duties to the Company's stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Derma's shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation.  The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation.  The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Faruqi & Faruqi, LLP is working together in this investigation with Juan E. Monteverde from Monteverde & Associates PC.

If you own common stock in Derma and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/DSCI or contact Nadeem Faruqi, Esq. either via e-mail at nfaruqi@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.  You may also contact Juan E. Monteverde, Esq.  either via email at jmonteverde@monteverdelaw.com or by telephone at (212) 971-1341.